Table 2. Single-Nucleotide Polymorphisms on Chromosome 6 Associated With Major Bleeding Risk in the Discovery and Replication Cohort.
| Single-Nucleotide Polymorphism | Minor Allele | Minor Allele Frequency, % | Discovery Cohort (n = 215) |
Replication Cohort (n = 188)a |
Meta-analysis (n = 403) |
|||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value | |||
| rs115112393 | G | 5 | 8.35 (3.2-21.5)b | 5.9 × 10−8 | ND | ND | ND | ND |
| rs16871327 | T | 5 | 8.31 (3.2-21.5)b | 6.21 × 10−8 | ND | ND | ND | ND |
| rs78132896c | C | 5 | 8.31 (3.2-21.5)b | 6.21 × 10−8 | 8.24 (3.1-25.3)d | 5.64 × 10−5 | 8.27 (4.18-16.38) | 2.05 × 10−11 |
| 9.38 (3.4-26.1)e | 1.81 × 10−5 | |||||||
| rs114504854 | A | 5 | 8.30 (3.2-21.5)b | 6.23 × 10−8 | ND | ND | ND | ND |
Abbreviations: ND, not determined; OR, odds ratio.
a
Thriteen controls from the replication cohort failed genotyping, leading to decrease in sample size to 188.
b
Adjusted for abnormal renal function, principal component 1, principal component 2.
c
Meta-analysis P value of the discovery and replication cohorts for rs78132896.
d
Adjusted for abnormal renal function.
e
Adjusted for HAS-BLED (HAS-BLED: hypertension, abnormal renal or liver function, stroke, bleeding history, labile international normalized ratio, elderly, antiplatelet agents, nonsteroidal anti-inflammatory drugs or alcohol use).